{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sohn SH"],"funding":["National Evidence-based Healthcare Collaborating Agency"],"pagination":["536-546"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11538586"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["57(6)"],"pubmed_abstract":["<h4>Background</h4>This study compared the costs associated with transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR) in Korea by utilizing the National Health Insurance Service database.<h4>Methods</h4>Between June 2015 and May 2019, 1,468 patients underwent primary isolated transfemoral TAVI, while 2,835 patients received primary isolated SAVR with a bioprosthesis. We assessed the costs of index hospitalization and subsequent healthcare utilization, categorizing the cohort into 6 age subgroups: <70, 70-74, 75-79, 80-84, 85-89, and ≥90 years. The median follow-up periods were 2.5 and 3.0 years in the TAVI and SAVR groups, respectively.<h4>Results</h4>The index hospitalization costs were 41.0 million Korean won (KRW) (interquartile range [IQR], 39.1-4"],"journal":["Journal of chest surgery"],"pubmed_title":["Costs Associated with Transcatheter Aortic Valve Implantation and Surgical Aortic Valve Replacement in Korea."],"pmcid":["PMC11538586"],"funding_grant_id":["HC21C0180010021"],"pubmed_authors":["Lim C","Shinn SH","Lee SH","Sohn SH","Kim KH","Choi JW","Kang Y","Yoo JS"],"additional_accession":[]},"is_claimable":false,"name":"Costs Associated with Transcatheter Aortic Valve Implantation and Surgical Aortic Valve Replacement in Korea.","description":"<h4>Background</h4>This study compared the costs associated with transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR) in Korea by utilizing the National Health Insurance Service database.<h4>Methods</h4>Between June 2015 and May 2019, 1,468 patients underwent primary isolated transfemoral TAVI, while 2,835 patients received primary isolated SAVR with a bioprosthesis. We assessed the costs of index hospitalization and subsequent healthcare utilization, categorizing the cohort into 6 age subgroups: <70, 70-74, 75-79, 80-84, 85-89, and ≥90 years. The median follow-up periods were 2.5 and 3.0 years in the TAVI and SAVR groups, respectively.<h4>Results</h4>The index hospitalization costs were 41.0 million Korean won (KRW) (interquartile range [IQR], 39.1-4","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Nov","modification":"2026-07-16T13:08:39.031Z","creation":"2025-04-04T03:04:30.557Z"},"accession":"S-EPMC11538586","cross_references":{"pubmed":["39434612"],"doi":["10.5090/jcs.24.048"]}}